- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
New Role for Former FDA Commissioner Hamburg
FDA commissioner Margaret Hamburg has received praise and plaudits as she exits the Food and Drug Administration this week after six years on the job.
Former FDA commissioner Margaret A. (Peggy) Hamburg has been appointed as the next foreign secretary of the Institute of Medicine (IOM), the health arm of the National Academy of Sciences. In the part-time position, Hamburg will serve as a senior adviser on international matters to the IOM president and council and as liaison to foreign academies of medicine and science. According to NAS, Hmaburg's term began April 6 and is effective through June 30, 2019.
"Global engagement and impact are strategically important for the IOM. I am delighted that Peggy has agreed to take on this important responsibility," said IOM president Victor J. Dzau. Established in 1970 under the charter of the National Academy of Sciences, the Institute of Medicine provides independent, objective, evidence-based advice to policymakers, health professionals, the private sector, and the public
Yescarta Demonstrates Promise in Treating Relapsed/Refractory Large B-Cell Lymphoma
December 9th 2024Real-world evidence from the largest analysis of second-line treatment with Yescarta in 2022-2023 demonstrated a high overall survival rate in patients with relapsed/refractory large b-cell lymphoma.
FDA Grants Priority Review to AstraZeneca’s Imfinzi for Muscle-Invasive Bladder Cancer
December 6th 2024The FDA based the Priority Review designation on results from the Phase III NIAGARA trial, which found that Imfinzi reduced the risk of disease progression, recurrence, or death by 32% in patients with muscle-invasive bladder cancer.
